This study suggested that m6A methylation regulators played an important role in head and neck tumor progression and demonstrates that IGF2BP2 and IGF2BP3 were prognostic indicators and potential biomarkers for immunotherapy in OSCC and OED. The gene discussed is IGF2BP2; the disease is head and neck neoplasm.